insights_auto
Nega 688235 oshdi 4,06%?
Batafsil oʻrganishchevron_right
688235:SHA
BeOne Medicines AG
255,98 CN¥
arrow_upward
+4,06%(+9,99) 1K
16-okt, 15:00:00 (GMT+8) · CNY
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto688235 tikeri uchun statistika yaratilmoqda...
Ochish
253,20 CN¥
Yuqori
268,18 CN¥
Past
252,09 CN¥
Bozor kapitali
303,26 mlrd
Oʻrtacha hajm
2,81 mln
Hajmi
5,69 mln
P/E koeffitsiyenti
91,43
52 haftalik eng yuqori
319,24 CN¥
52 haftalik eng past
205,51 CN¥
Aksiya boʻyicha daromad
2,80 CN¥
Xodimlar soni
12 ming
Ochish
253,20 CN¥
Yuqori
268,18 CN¥
Past
252,09 CN¥
Bozor kapitali
303,26 mlrd
Oʻrtacha hajm
2,81 mln
Hajmi
5,69 mln
P/E koeffitsiyenti
91,43
52 haftalik eng yuqori
319,24 CN¥
52 haftalik eng past
205,51 CN¥
Aksiya boʻyicha daromad
2,80 CN¥
Xodimlar soni
12 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
ad-hoc-news.de
·
19 soat oldin
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
BeOne Medicines AG haqida
CEOJohn Vincent Oyler | John Vincent Oyler
Xodimlar soni12 ming
Asos solingan28-okt, 2010
Bosh ofislar-
Sektor-
Veb-saytbeonemedicines.com